Celldex Therapeutics, Inc.
CLDXNASDAQHealthcare● Active
$28.63
+$0.01(+0.03%)
Market Cap$1.9B
P/E Ratio—
52W High$35.79
52W Low$19.25
Celldex Therapeutics, Inc. (CLDX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CLDX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.50M | $7.02M | $6.88M | $2.36M | $4.65M |
| Cost of Revenue | $0.00M | $163.55M | $118.01M | $82.26M | $53.31M |
| Gross Profit | $1.50M | ($156.53M) | ($111.13M) | ($79.90M) | ($48.66M) |
| Gross Margin %(computed) | 100.00% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $245.10M | $163.55M | $118.01M | $82.26M | $56.81M |
| G&A Expenses | $43.80M | $38.55M | $30.91M | $27.20M | $20.49M |
| Total Operating Expenses | $288.90M | $38.55M | $43.41M | $35.33M | $22.58M |
| Operating Income | ($287.40M) | ($195.08M) | ($154.54M) | ($115.23M) | ($71.24M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $28.61M | $37.22M | $13.11M | $2.91M | $0.51M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($258.80M) | ($157.86M) | ($141.43M) | ($112.33M) | ($70.74M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | ($0.23M) |
| Net Income | ($258.80M) | ($157.86M) | ($141.43M) | ($112.33M) | ($70.51M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.90 | $-2.45 | $-2.92 | $-2.40 | $-1.64 |
| Wtd Avg Shares | 66.50M | 64.39M | 48.45M | 46.89M | 42.87M |
| EBITDA | ($255.42M) | ($191.90M) | ($139.03M) | ($104.20M) | ($66.08M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Celldex Therapeutics, Inc. data
About Celldex Therapeutics, Inc. (CLDX) Income Statement
Celldex Therapeutics, Inc. (CLDX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CLDX reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.26B) — a net profit margin of -17253.33%.
Frequently asked questions
CLDX · 4 questionsCelldex Therapeutics, Inc. (CLDX) reported revenue of $0.00B for 2025, down 78.6% year-over-year.
CLDX revenueCLDX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08